Navigation Links
The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
Date:10/7/2008

ogether microbiologists, molecular biologists, synthetic chemists, medicinal chemists, pharmacologists, toxicologists, and process chemists to expedite the testing and optimizing of early-stage compounds to fill the pipeline for drug development.

"This Initiative is founded on the belief that people from different corners of the pharmaceutical and healthcare world will put aside differences and come together when confronted with a global threat," said Dr. Gail Cassell, Lilly's vice president of scientific affairs and distinguished research scholar. "Our collaboration around these two compounds proves that this belief is true. We are encouraged by the response and inspired by the commitment of our colleagues."

Over the past year, The Lilly TB Drug Discovery Initiative has organized operations and labs and identified compounds for the first round of work. Within the next few months, it plans to begin high-throughput screening of new, validated targets against well-characterized chemical libraries.

In addition to screening activities, the Initiative will study the potential of the newly acquired compounds from MCRF and Summit plc:

-- MCRF has discovered CPZEN-45, an early stage clinical candidate which may have a new mechanism of action against TB, and also shows efficacy against multidrug-resistant and extensively drug resistant TB infected mice without any detectable side effect so far examined.

-- Summit plc's compounds also show significant potential as a new class of antibiotics for treatment of TB and will be further explored by the Initiative.

Organizations co-developing compounds with the Initiative or contributing research tools will have the opportunity to request access to NIH-sponsored resources and receive valuable data to assist the Initiative's research process.

More than 1.5 million people die each year from TB, most of them in low income countries. However, TB is spreading globally and evolving rapidly i
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
2. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
5. Amylin and Lilly Set Date and Time for Conference Call
6. Lilly Announces Completion of SGX Acquisition
7. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
8. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
9. Lilly Reports Solid Second-Quarter Results
10. Lilly to Acquire SGX Pharmaceuticals
11. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... Vernon Hills, IL (PRWEB) January 15, 2014 ... Cole-Parmer to find hard-working items for the lab, from ... designated as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
Breaking Biology Technology:Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... SHANGHAI, Sep. 4 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: ... Chinese firm,specializing in the manufacture, research, development, marketing ... Company,s,management team will attend the Susquehanna International Group ... The SIG 3rd Annual ...
... , AURORA, Ontario, Sept. 4 Helix BioPharma ... has accepted subscriptions for the purchase, by way of private placement, ... gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private ... unit consists of one common share and one common share purchase ...
... Kendle (Nasdaq: KNDL ), a leading, global full-service ... the upcoming Robert Baird 2009 Health Care Conference on Sept. ... New York City. , , (Logo: ... Kendle,s formal presentation will be given by Senior Vice President ...
Cached Biology Technology:China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit 2Helix BioPharma Announces $13.5 Million Private Placement 2Kendle to Present at Robert Baird 2009 Health Care Conference 2
(Date:7/10/2014)... even improve the state of fisheries resources in ... Mediterranean has deteriorated over the past 20 years. ... reported in the Cell Press journal Current ... stringent monitoring of Mediterranean fishing activities, better enforcement ... Mediterranean waters. , Their data show that the ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... company housed at NJIT,s business incubator, received a $1.4 ... surgeons will use to staunch bleeding during brain surgery. ... site, and the natural bio-polymer solutions in the gel ... 30 seconds. , The gel can shorten an ... into less time for the patient,s skull to be ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... , This release is also available in Chinese ... it the anti-sunscreen. That,s more or less the description of ... light-catching substances that could be added to photovoltaic materials in ... electricity. Research reported in the journal ...
... 2010) Autism Speaks, Chief Science Officer Geraldine ... environmental risk factors for autism spectrum disorders as ... Works, Subcommittee on Children,s Health convened a special ... autism spectrum disorders (ASD) and related neurodevelopmental disorders. ...
... for two competitive grants to better understand and manage outbreaks ... fisheries in Puget Sound. The grants cover the first year ... the next three years. NEW FORECAST ... goal of one project is to develop a forecasting ability ...
Cached Biology News:Selenium makes more efficient solar cells 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 3New research to improve management of harmful algal blooms in Puget Sound 2
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
... The versatile Promega Flipper® Racks are ... of your small tubes. These polypropylene racks ... choice for freezer storage. They may also ... Each rack is two-sided; one side accommodates ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
Biology Products: